Solid Biosciences Announces Pricing of Underwritten Offering

Core Viewpoint - Solid Biosciences Inc. has announced the pricing of an underwritten offering of 35,739,810 shares of common stock at $4.03 per share, along with pre-funded warrants for 13,888,340 shares at $4.029 each, aiming for approximately $200 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes both new and existing investors, such as Adage Capital Partners LP, Bain Capital Life Sciences, and several other institutional investors [2]. - The offering is expected to close on or about February 19, 2025, pending customary closing conditions [1]. - Jefferies, Leerink Partners, and William Blair are acting as joint book-running managers, while H.C. Wainwright & Co. serves as the lead manager [3]. Group 2: Securities Registration - The securities are being offered under a shelf registration statement on Form S-3, which was declared effective by the SEC on May 17, 2024 [4]. - A final prospectus supplement will be filed with the SEC, and copies will be available through the mentioned financial institutions [4]. Group 3: Company Overview - Solid Biosciences focuses on developing precision genetic medicines for neuromuscular and cardiac diseases, including conditions like Duchenne muscular dystrophy and Friedreich's ataxia [6]. - The company aims to advance a diverse pipeline of gene therapy candidates and innovative technologies to improve patient outcomes [6].